Bringing Health Care Providers Together to Diagnose and Treat Idiopathic Pulmonary Fibrosis: A Patient SimulationPremiere Date: Tuesday, July 18, 2017
This activity offers CE credit for:%>
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, July 18, 2018
Note: Credit Is No Longer Available
|Steven D. Nathan, MD, FCCP (Moderator)
Medical Director, Lung Transplant Program
Director, Advanced Lung Disease Program
Inova Fairfax Hospital
Professor of Medicine
Virginia Commonwealth University, Inova Fairfax Campus
Falls Church, VA
|Jonathan H. Chung, MD
Associate Professor of Radiology
Associate Section Chief, Thoracic Radiology
Director of Thoracic Quality Assurance
The University of Chicago Medicine
|Marilyn K. Glassberg, MD
Professor of Medicine, Surgery, and Pediatrics
Director, Interstitial Lung Disease Program
Chief, Pulmonary Division at Interdisciplinary Stem Cell Institute
Vice-Chairman of Medicine for Diversity and Innovation
Department of Medicine
University of Miami Miller School of Medicine
Although the most common of the restrictive lung diseases, idiopathic pulmonary fibrosis (IPF) is a rare but deadly disease, affecting an estimated 6.8 to 42.7 per 100,000 people, with higher rates in those older than 65 years, and resulting in approximately 40,000 deaths annually in the United States.1
Education to community pulmonologists, radiologists, and primary care physicians, as well as the multidisciplinary team is important to increase knowledge related to recognition and diagnosis. Clinicians need to be aware of when to refer patients with potential IPF to specialty centers with pulmonologists, radiologists, and pathologists specialized in interstitial lung disease (ILD). All providers in the multidisciplinary and multispecialty treatment team need education related to recent ATS/ERS/JRS/ALAT guidelines and mechanisms of action for the approved treatments for IPF.
In this CME Outfitters decision-tree medical simulation participants will navigate the clinical challenges presented by a patient with IPF. Expert faculty will highlight the latest evidence and guidelines for IPF including when to refer and best treatment approach.
1. Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2014;2(7):566-572.
At the end of this CE activity, participants should be able to:
- Identify the signs and symptoms of idiopathic pulmonary fibrosis.
- Outline the red flags that would trigger an expeditious referral of a patient with dyspnea to a multidisciplinary team.
- Combine information derived from guidelines and studies of newly approved and emerging therapies in identifying a treatment approach for the patient with IPF.
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Supported by an educational grant from Genentech.
Pulmonologists, radiologists, primary care physicians, PAs, NPs, nurses, pharmacists
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1 contact hour
Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1 contact hours of pharmacotherapeutic contact hours.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.0 contact hours (0.10 CEUs) Universal Activity Number:
Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Steven D. Nathan, MD, FCCP has disclosed that he receives research support from Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc./Roche. He is a member of the speakers bureau for Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc./Roche. He is a consultant for Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc./Roche.
Jonathan H. Chung, MD has no disclosures to report.
Marilyn K. Glassberg, MD has disclosed that she receives research support from Genentech, Inc. She is a consultant for Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; and Patara Pharma.
Disclosures were obtained from the CME Outfitters, LLC staff: Nothing to Disclose
Daniela V. DiBiase, MS (planning committee) has no disclosures to report.
Jeffrey Helfand, DO, MS (peer reviewer) has no disclosures to report.
Kimberley Murray, RN, MS (peer reviewer) has no disclosures to report.
Jan Perez, CHCP (planning committee) has no disclosures to report.
Sharon Tordoff, CHCP (planning committee) has no disclosures to report.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).